Windlas Biotech Limited
WINDLAS
Rank in Stocks
#16360
Windlas Biotech Limited functions as a comprehensive contract development and... Windlas Biotech Limited functions as a comprehensive contract development and manufacturing organization (CDMO). Its CDMO offerings span the full product lifecycle, encompassing initial discovery, subsequent development, licensing, and large-scale commercial production of various generic pharmaceutical and nutraceutical items. Through these services, it assists clients in bringing both established and innovative pharmaceutical and nutraceutical products to market, which are then sold under the clients' proprietary brand names. Beyond its CDMO segment, Windlas Biotech also develops and manufactures its own portfolio of domestic trade generics and over-the-counter (OTC) brands, catering to the nutritional, ayurvedic, wellness, and personal care sectors. These in-house products reach consumers via a dual distribution approach: traditional offline channels like distributors, stockists, retail pharmacies, and institutional tenders, alongside a robust online presence through various e-commerce platforms. The company's international reach extends through exports, primarily to markets such as Vietnam, Myanmar, Sri Lanka, Thailand, the Philippines, Cambodia, Fiji, Trinidad & Tobago, and South Africa. Established in 2001, Windlas Biotech is headquartered in Gurugram, India.
Share Price
$10.37
Last synced: 2026-11-09
Market Cap
$214.00M
Change (1 day)
-1.49%
Change (1 year)
9.50%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Windlas Biotech Limited (WINDLAS)
Category
Healthcare
EPS for Windlas Biotech Limited (WINDLAS)
EPS as of June 2026 TTM: $0.33
According to Windlas Biotech Limited's latest financial reports, its current EPS (TTM) is $0.33. At the end of 2025 the company had an EPS of $0.34, equal to its 2024 EPS of $0.34.
EPS history for Windlas Biotech Limited from 2018 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $0.33 | -1.97% |
| 2025 | $0.34 | 1.70% |
| 2024 | $0.34 | 39.92% |
| 2023 | $0.24 | -2.08% |
| 2022 | $0.24 | 106.06% |
| 2021 | $0.12 | 0.59% |
| 2020 | $0.12 | -71.99% |
| 2019 | $0.42 | 289.02% |
| 2018 | $0.11 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $6.50 | 1,850.62% |
DE
|
|
| $6.08 | 1,723.46% |
DE
|
|
| $1.55 | 365.23% |
JP
|
|
| $3.66 | 998.11% |
CH
|
|
| $0.45 | 35.01% |
IL
|
Questions about Windlas Biotech Limited's earnings per share (EPS)
What is Windlas Biotech Limited's earnings per share (EPS)?
Windlas Biotech Limited's earnings per share (EPS) over the last twelve months is $0.33, as of Jun 2026.
What was Windlas Biotech Limited's earnings per share (EPS) in 2025?
In 2025, Windlas Biotech Limited's earnings per share (EPS) was $0.34, about the same as in 2024 ($0.34).
How has Windlas Biotech Limited's earnings per share (EPS) changed since 2020?
From 2020 to 2025, Windlas Biotech Limited's earnings per share (EPS) went from $0.12 to $0.34, an average growth of 23.16% a year.
How does Windlas Biotech Limited's earnings per share (EPS) compare with similar companies?
Windlas Biotech Limited's earnings per share (EPS) ($0.33) is lower than that of all 5 similar companies listed above. The highest among them is MERCK Kommanditgesellschaft auf Aktien, with $6.50.